We are live on
!
Find out more
BAMCO Inc Portfolio holdings
AUM
$33.1B
1-Year Est. Return
11.16%
This Fund
S&P 500
This Quarter
Est. Return
+7.81%
1 Year Est. Return
+11.16%
3 Year Est. Return
+63.39%
5 Year Est. Return
+85.45%
10 Year Est. Return
+744.36%
AUM
$37.7B
AUM Growth
+$825M
(+2.2%)
Cap. Flow
-$555M
Cap. Flow
% of AUM
-1.47%
Top 10 Holdings %
Top 10 Hldgs %
42.45%
Holding
343
New
37
Increased
135
Reduced
115
Closed
13
Top Buys
| 1 |
Gartner
IT
|
+$195M |
| 2 |
MSCI
MSCI
|
+$127M |
| 3 |
Birkenstock
BIRK
|
+$91.8M |
| 4 |
Loar Holdings
LOAR
|
+$84.7M |
| 5 |
Aaon
AAON
|
+$59.5M |
Top Sells
| 1 |
Tesla
TSLA
|
+$372M |
| 2 |
Iridium Communications
IRDM
|
+$190M |
| 3 |
Factset
FDS
|
+$158M |
| 4 |
Chart Industries
GTLS
|
+$146M |
| 5 |
Kratos Defense & Security Solutions
KTOS
|
+$138M |
Sector Composition
| 1 | Consumer Discretionary | 30.84% |
| 2 | Financials | 20.19% |
| 3 | Technology | 18.62% |
| 4 | Real Estate | 8.92% |
| 5 | Healthcare | 8.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Teva Pharmaceuticals
TEVA
$37.1B
| $2.22M | 0.01% |
110,000
+10,000
| +10% | +$176K |
|
277
Freshpet
FRPT
$2.67B
| $2.13M | 0.01% |
38,628
+52
| +0.1% | +$3.22K |
|
278
Lumentum
LITE
$63.4B
| $2.05M | 0.01% |
+12,582
| New | +$1.57M |
|
279
Coherent
COHR
$60.8B
| $2.05M | 0.01% |
18,994
+9,792
| +106% | +$976K |
|
280
Vertex Pharmaceuticals
VRTX
$121B
| $2.04M | 0.01% |
5,200
-3,800
| -42% | -$1.59M |
|
281
Doximity
DOCS
$3.99B
| $1.98M | 0.01% |
27,000
+12,000
| +80% | +$782K |
|
282
Robert Half
RHI
$3.65B
| $1.96M | 0.01% |
57,600
| – | – |
|
283
Lam Research
LRCX
$433B
| $1.81M | ﹤0.01% |
13,529
-1,039
| -7% | -$110K |
|
284
Insulet
PODD
$11B
| $1.76M | ﹤0.01% |
5,700
| – | – |
|
|
CDTX
285
DELISTED
Cidara Therapeutics
CDTX
| $1.68M | ﹤0.01% |
+17,500
| New | +$1.12M |
|
286
Alexandria Real Estate Equities
ARE
$8.28B
| $1.68M | ﹤0.01% |
20,104
-135,902
| -87% | -$10.9M |
|
287
Ionis Pharmaceuticals
IONS
$9.08B
| $1.64M | ﹤0.01% |
+25,000
| New | +$1.22M |
|
288
Progressive
PGR
$132B
| $1.63M | ﹤0.01% |
6,600
-1,400
| -18% | -$345K |
|
289
Alnylam Pharmaceuticals
ALNY
$37.6B
| $1.6M | ﹤0.01% |
+3,500
| New | +$1.43M |
|
290
Roivant Sciences
ROIV
$25.1B
| $1.59M | ﹤0.01% |
+105,000
| New | +$1.3M |
|
291
UnitedHealth
UNH
$386B
| $1.48M | ﹤0.01% |
+4,300
| New | +$1.3M |
|
292
Manchester United
MANU
$3.8B
| $1.37M | ﹤0.01% |
90,448
| – | – |
|
293
Cytokinetics
CYTK
$11.1B
| $1.35M | ﹤0.01% |
+24,500
| New | +$1.01M |
|
|
CFLT
294
DELISTED
Confluent
CFLT
| $1.29M | ﹤0.01% |
65,000
-100,000
| -61% | -$2.09M |
|
295
Blackrock
BLK
$159B
| $1.28M | ﹤0.01% |
1,100
| – | – |
|
296
Xenon Pharmaceuticals
XENE
$6.51B
| $1.2M | ﹤0.01% |
30,000
-26,000
| -46% | -$916K |
|
297
Madrigal Pharmaceuticals
MDGL
$12.4B
| $1.19M | ﹤0.01% |
+2,600
| New | +$970K |
|
|
NVO
298
Novo Nordisk
NVO
$217B
| $1.19M | ﹤0.01% |
21,441
| – | – |
|
|
ABVX
299
Abivax
ABVX
$11.8B
| $1.19M | ﹤0.01% |
+14,000
| New | +$858K |
|
300
Ascendis Pharma A/S
ASND
$17.4B
| $1.11M | ﹤0.01% |
+5,600
| New | +$1.04M |
|
Similar funds
PPF
GAM
TWC
